Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...

Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...

Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share.

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...